Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK0214 in AMN Form of X-ALD
NCT04973657Phase 1Completed
- Sponsor
- Viking Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of VK0214 in X-linked adrenoleukodystrophy (X-ALD) (3 arms), sponsored by Viking Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at 28 days. Started Jun 2021; status: completed.
02
Drugs
VK0214
03
Conditions
X-linked adrenoleukodystrophy (X-ALD)
Beyond the preview
Go deeper on NCT04973657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973657.